AstraZeneca Non-GAAP EPS of $1.72 beats by $0.14, revenue of $10.77B beats by $250M
AstraZeneca press release  (NASDAQ:AZN): Q2  Non-GAAP EPS of $1.72  beats by $0.14.
Revenue of $10.77B (+31.0% Y/Y)  beats by $250M.
Growth across Breztri and Fasenra offsetting a decline in Pulmicort of 30% (28% at CER) primarily due to the impact of VBP implementation and COVID-19 lockdowns in China.
$455m from Vaxzevria21 , $445m from Evusheld. Majority of Vaxzevria revenue from initial contracts.